Retatrutide for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 10 registered trials.

Why this status

  1. 3 Jul 2023: Trial registered, NCT05929079
  2. 11 Jul 2023: Trial started, NCT05929079
  3. 15 Feb 2024: Trial registered, NCT06260722
  4. 21 Feb 2024: Trial started, NCT06260722
  5. 7 Mar 2024: Trial registered, NCT06297603
  6. 15 Mar 2024: Trial started, NCT06297603
  7. 9 Apr 2024: Trial registered, NCT06354660
  8. 10 Apr 2024: Trial started, NCT06354660
  9. 25 Apr 2024: Trial registered, NCT06383390
  10. 30 Apr 2024: Trial started, NCT06383390

The trials

NCT04143802: A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

State
Completed
Phase
Phase 1
People
72 taking part
Started
18 Dec 2019
Primary completion
28 Dec 2020
Arms
LY3437943
Results
None posted
  1. 29 Oct 2019: Trial registered
  2. 18 Dec 2019: Trial started
  3. 28 Dec 2020: Trial completed

NCT04823208: A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

State
Completed
Phase
Phase 1
People
64 taking part
Started
24 May 2021
Primary completion
23 Jun 2022
Arms
LY3437943
Results
None posted
  1. 30 Mar 2021: Trial registered
  2. 24 May 2021: Trial started
  3. 23 Jun 2022: Trial completed

NCT04867785: A Study of LY3437943 in Participants With Type 2 Diabetes

State
Completed
Phase
Phase 2
People
281 taking part
Started
13 May 2021
Primary completion
8 Jul 2022
Arms
0.5 milligrams (mg) LY3437943, 4 mg LY3437943 (2 mg), 4 mg LY3437943 (4 mg), 8 mg LY3437943 (2 mg), 8 mg LY3437943 (4 mg), 12 mg LY3437943 (2 mg)
Results
Posted on the registry
  1. 30 Apr 2021: Trial registered
  2. 13 May 2021: Trial started
  3. 27 Oct 2022: Trial completed
  4. 3 Jul 2023: Trial results posted

NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

State
Completed
Phase
Phase 3
People
1,152 taking part
Started
11 Jul 2023
Primary completion
16 Jun 2026
Arms
Retatrutide Dose 1, Retatrutide Dose 2, Retatrutide Dose 3
Results
None posted
  1. 3 Jul 2023: Trial registered
  2. 11 Jul 2023: Trial started
  3. 16 Jun 2026: Trial completed

NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

State
Completed
Phase
Phase 2
People
146 taking part
Started
20 Jul 2023
Primary completion
1 Oct 2025
Arms
Retatrutide
Results
Posted on the registry
  1. 7 Jul 2023: Trial registered
  2. 20 Jul 2023: Trial started
  3. 21 Oct 2025: Trial completed
  4. 9 Nov 2026: Trial results posted

NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

State
Under way
Phase
Phase 3
People
1,250 planned
Started
21 Feb 2024
Primary completion
27 Aug 2026
Arms
Retatrutide Dose Level 1, Retatrutide Dose Level 2
Results
None posted
  1. 15 Feb 2024: Trial registered
  2. 21 Feb 2024: Trial started

NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

State
Under way
Phase
Phase 3
People
341 taking part
Started
15 Mar 2024
Primary completion
26 Oct 2026
Arms
Retatrutide Dose 1, Retatrutide Dose 2, Retatrutide Dose 3
Results
None posted
  1. 7 Mar 2024: Trial registered
  2. 15 Mar 2024: Trial started

NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

State
Completed
Phase
Phase 3
People
537 taking part
Started
10 Apr 2024
Primary completion
22 Jan 2026
Arms
Retatrutide Dose Level 1, Retatrutide Dose Level 2, Retatrutide Dose Level 3
Results
None posted
  1. 9 Apr 2024: Trial registered
  2. 10 Apr 2024: Trial started
  3. 20 Feb 2026: Trial completed

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

State
Under way
Phase
Phase 3
People
10,000 planned
Started
30 Apr 2024
Primary completion
Feb 2029
Arms
Retatrutide
Results
None posted
  1. 25 Apr 2024: Trial registered
  2. 30 Apr 2024: Trial started

NCT06982846: A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

State
Completed
Phase
Phase 1
People
80 taking part
Started
6 Jun 2025
Primary completion
4 May 2026
Arms
Retatrutide
Results
None posted
  1. 21 May 2025: Trial registered
  2. 6 Jun 2025: Trial started
  3. 4 May 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Retatrutide (LY3437943).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.